SALT LAKE CITY , Feb. 27, 2019 /PRNewswire/ -- PolarityTE, Inc. ( PTE ) announced today that its platform technology will be featured at the 2019 Pacific Operational Science and Technology (POST) Conference, co-sponsored by the United States Indo-Pacific Command and TechConnect, held March 4-8, 2019 . PolarityTE is a commercial-stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences.
Two poster presentations that highlight the regenerative capacities of the PolarityTE platform technology will be presented during the conference. The presentations will detail clinical use of the SkinTE™ product, a first-of-its-kind autologous, homologous human cellular and tissue-based product designed to regenerate full-thickness, functional skin for skin repair, reconstruction and replacement, and preclinical studies involving the use of the technology for regeneration of bone.
The POST Conference brings together senior U.S. Department of Defense leaders from the operational and research and development communities, senior leaders from the international science and technology community, industry executives, engineers, university representatives and scientists. For the past 19 years, this conference has served as a venue for participants to understand operational issues in the Indo-Asia Pacific region and for technology providers to recommend scientific and technological solutions that will address these challenges and strengthen alliances in the region.
"We are honored to be included in the Pacific Operational Science and Technology Conference, which provides a rare opportunity to share the science of our unique technology with leaders at the U.S. Department of Defense and to learn more about the needs of combat personnel. Since our founding, we have appreciated the potential to accelerate healing for members of the U.S. armed services and its allied partners, and we look forward to continuing our efforts to deliver true tissue regeneration to all patients in need," said Denver M. Lough , MD, PhD, Chairman and Chief Executive Officer of PolarityTE.
PolarityTE is a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. Rather than manufacturing with synthetic and foreign materials within artificially engineered environments, PolarityTE manufactures with the patient's own tissue and uses the patient's own body to support the regenerative process to create the same tissue from which it was derived. From a small piece of healthy autologous tissue, the company creates an easily deployable, dynamic and self-propagating product designed to regenerate the target tissues. PolarityTE's innovative method is intended to promote and accelerate growth of the patient's tissues to undergo a form of effective regenerative healing. Learn more at www.PolarityTE.com – Welcome to the Shift ® .
SkinTE is a human cellular and tissue-based product derived from a patient's own skin intended for the repair, reconstruction, and replacement of skin tissue. SkinTE results have shown the regeneration of full-thickness (epidermis, dermis and hypodermis), functionally-polarized skin with all the appendages including hair and glands.
SkinTE is intended to be used by physicians or other appropriate healthcare providers for homologous uses of skin tissues/integument. Patients who have suffered from an event, disease, process or acquired deficit that results in the functional loss or void of skin/integument systems can receive SkinTE as an adjunct and/or in place of split-thickness skin grafting, full-thickness grafting, temporizing skin coverage and/or skin substitute products. SkinTE is for autologous use only. Aseptic technique during harvest and deployment of SkinTE is mandatory. SkinTE is marketed as an HCT/P regulated by the FDA solely under Section 361 of the Public Health Service Act and 21 CFR 1271.
Forward Looking Statements
Certain statements contained in this release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. They are generally identified by words such as "believes," "may," "expects," "anticipates," "intend," "plan," "will," "would," "should" and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company's beliefs and assumptions as of the date of this release. The Company's actual results could differ materially due to risk factors and other items described in more detail in the "Risk Factors" section of the Company's Annual Reports and other filings with the SEC (copies of which may be obtained at www.sec.gov ). Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law. Our actual results could differ materially due to risk factors and other items described in more detail in the "Risk Factors" section of the Company's Annual Reports and other filings with the SEC (copies of which may be obtained at www.sec.gov ).
POLARITYTE, the POLARITYTE logo, WHERE SELF REGENERATES SELF, WELCOME TO THE SHIFT, and SKINTE are trademarks or registered trademarks of PolarityTE, Inc.
VP, Investor Relations
LifeSci Advisors, LLC
View original content to download multimedia: http://www.prnewswire.com/news-releases/polarityte-presents-platform-technology-at-department-of-defense-pacific-operational-science-and-technology-post-conference-300802891.html